ISE alum has 25 years of experience in strategy, collaborations for pharma, biotech companies

Industrial engineering alum Karen LaRochelle '88 has been appointed senior vice president of corporate and business development for WindMIL Therapeutics, a clinical-stage company, based in Baltimore and Philadelphia, that is developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy.

LaRochelle will be responsible for facilitating business growth, defining partnering strategy, spearheading collaborations, and evaluating new corporate and business development opportunities. She joins WindMIL with more than 25 years of industry experience focused on strategy and collaborations for pharmaceutical and biotechnology companies in the United States, Europe, and China, including strategic collaborations, mergers and acquisitions, and licensing.

Previously, she was chief business officer of PsiOxus Therapeutics and she also provided multiple biotechnology companies with business development and collaboration consulting services. Prior to that, LaRochelle spent nearly 20 years with Bristol-Myers Squibb, most recently as global head of negotiations and head of business development in China.

She received her MBA from Columbia University and BS in industrial engineering from Lehigh, where she currently serves on the Dean's Advisory Council, the external consultative group supporting the dean of the P.C. Rossin College of Engineering and Applied Science.

Accordinng to chairman and chief executive officer Don Hayden, LaRochelle will help WindMIL to continue to advance understanding of the benefits the company's "novel class of autologous cell therapies for cancer immunotherapy might provide to cancer patients.”
 

About WindMIL Therapeutics

WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow infiltrating lymphocytes (MILs™) for cancer immunotherapy. As the leader in cellular therapeutics emanating from bone marrow, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients. The company’s proprietary process to activate and expand these cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxic potential and long persistence.

Karen LaRochelle

Karen LaRochelle '88, an industrial engineering alum, has been appointed senior vice president of corporate and business development for WindMIL Therapeutics.